ES2114687T3 - Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos. - Google Patents

Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos.

Info

Publication number
ES2114687T3
ES2114687T3 ES94915562T ES94915562T ES2114687T3 ES 2114687 T3 ES2114687 T3 ES 2114687T3 ES 94915562 T ES94915562 T ES 94915562T ES 94915562 T ES94915562 T ES 94915562T ES 2114687 T3 ES2114687 T3 ES 2114687T3
Authority
ES
Spain
Prior art keywords
antigens
ospc
prevention
preparation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915562T
Other languages
English (en)
Inventor
Ian Livey
Brian Crowe
Friedrich Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of ES2114687T3 publication Critical patent/ES2114687T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN ENFOQUE EN LA FORMULACION DE VACUNA BORRELIA, TOMANDO EN CUENTA LA INFORMACION SEROLOGICA, GENOTIPICA Y EPIDEMIOLOGICA POR LA QUE LAS PROTEINAS OSPC DE DIFERENTES RAMIFICACIONES DE B. BURGDORFERI SON AGRUPADOS ENTRE SI. LOS ANTIGENOS OSPC SON ELEGIDOS PARA CONSTITUIR UNA MUESTRA REPRESENTATIVA DE TALES GRUPOS, DE MANERA QUE LA VACUNA RESULTANTE PROPORCIONA LA MAYOR PROTECCION CRUZADA CON EL MENOR NUMERO DE ANTIGENOS.
ES94915562T 1993-04-29 1994-04-29 Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos. Expired - Lifetime ES2114687T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5386393A 1993-04-29 1993-04-29

Publications (1)

Publication Number Publication Date
ES2114687T3 true ES2114687T3 (es) 1998-06-01

Family

ID=21987063

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915562T Expired - Lifetime ES2114687T3 (es) 1993-04-29 1994-04-29 Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos.

Country Status (16)

Country Link
EP (1) EP0701612B1 (es)
JP (1) JPH08509371A (es)
AT (1) ATE162550T1 (es)
AU (1) AU683260B2 (es)
CA (1) CA2161534A1 (es)
CZ (1) CZ289212B6 (es)
DE (1) DE69408135T2 (es)
DK (1) DK0701612T3 (es)
ES (1) ES2114687T3 (es)
FI (1) FI955150A (es)
HR (1) HRP940279B1 (es)
HU (1) HU217024B (es)
NO (1) NO954318L (es)
PL (1) PL178775B1 (es)
SK (1) SK279968B6 (es)
WO (1) WO1994025596A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5915049A (en) * 1992-02-25 1999-06-22 Pfu Limited Binarization system for an image scanner
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ATE232212T1 (de) * 1996-05-02 2003-02-15 Dako As Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
AT405940B (de) * 1996-06-21 1999-12-27 Immuno Ag Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
DE19740735A1 (de) * 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
AU5328299A (en) * 1998-07-31 2000-02-21 Gundersen Lutheran Medical Foundation, Inc. Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
DE60030859T2 (de) 1999-06-18 2007-06-14 The Research Foundation Of State University Of New York Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
DE60131982T2 (de) 2000-08-18 2008-12-11 Brookhaven Science Associates Llc Veränderte borrelia burgdorferi ospa
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
JP5390189B2 (ja) * 2005-11-29 2014-01-15 ヴァージニア コモンウェルス ユニバーシティ 多価キメラｏｓｐｃワクシノーゲンおよび診断用抗原
RU2460538C2 (ru) * 2006-11-03 2012-09-10 Шеринг-Плоу Лтд. Вакцина против лаймской болезни собак
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
CZ301548B6 (cs) * 2008-08-20 2010-04-14 Bittner@Libor Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease

Also Published As

Publication number Publication date
HRP940279A2 (en) 1997-10-31
ATE162550T1 (de) 1998-02-15
NO954318D0 (no) 1995-10-27
FI955150A0 (fi) 1995-10-27
WO1994025596A3 (en) 1994-12-22
AU6722994A (en) 1994-11-21
AU683260B2 (en) 1997-11-06
JPH08509371A (ja) 1996-10-08
NO954318L (no) 1995-12-29
CZ283995A3 (en) 1996-03-13
HU9502002D0 (en) 1995-08-28
SK134195A3 (en) 1996-05-08
EP0701612A1 (en) 1996-03-20
FI955150A (fi) 1995-12-28
CA2161534A1 (en) 1994-11-10
HU217024B (hu) 1999-11-29
CZ289212B6 (cs) 2001-12-12
PL311301A1 (en) 1996-02-05
DK0701612T3 (da) 1998-09-21
PL178775B1 (pl) 2000-06-30
HRP940279B1 (en) 2000-12-31
EP0701612B1 (en) 1998-01-21
DE69408135D1 (de) 1998-02-26
WO1994025596A2 (en) 1994-11-10
HUT72923A (en) 1996-06-28
DE69408135T2 (de) 1998-06-10
SK279968B6 (sk) 1999-06-11

Similar Documents

Publication Publication Date Title
ES2114687T3 (es) Formulacion inmunogena a base de antigenos ospc, destinada para la prevencion y para el tratamiento de la enfermedad de lyme y procedimientos de recombinacion para la preparacion de estos antigenos.
MX9204685A (es) Secuencia de adn que codifica una proteina superficial externa (ospa) o derivado de la misma composicion de vacuna qe comprende tal proteina.
FI904597A0 (fi) Vaccin mot lyme-sjukdom.
BR9305711A (pt) Vacina à base de urease contra infecção por helicobacter
NO913722L (no) Vaksinasjon og fremgangsmaater mot sykdommer som foelge av patogene responser fra spesifikke t-cellepopulasjoner.
YU134484A (en) Process for making oral imunogenic compositions
DE60030859D1 (de) Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
ES2075964T3 (es) Complejos inmunogenos, en particular iscomes.
ATE76548T1 (de) Verfahren und vorrichtung zur erzeugung von stereoskopischen bildern.
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
MX167117B (es) Topologia de red en anillo de fibras opticas
ES2096323T3 (es) Un rompecabezas.
AR001618A1 (es) Adyuvante de saponina del arbol quillajay y formulacion de vacuna que contiene el mismo
ES523563A0 (es) "un dispositivo mejorado de calentamiento para la obtencion de una fibra optica por estirado de una preforma"
DE69122240D1 (de) Antigen-wirkende proteine von borrelia burgdorferi
BR0315980A (pt) Antìgenos p153 e p156 para o diagnóstico imunológico da ehrlichiose canina e humana e uso dos mesmos
PT757556E (pt) Bacterina borrelia burgdorferi
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
EP0880543A4 (en) ANTIGENS AS VACCINE CANDIDATES FROM SPIROCHETE (BORRELIA BURGDORFERI) OF LIVE DISEASE INDUCED BY A SALT OF A TICK VECTOR (IXODES SCAPULARIS)
ES2146013T3 (es) Champues suaves para el cabello.
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
ES2056780T1 (es) Un procedimiento para el aislamiento de virus de hav.
ES2066933T3 (es) Barrera antirretorno.
ES2084082T3 (es) Cabezal trenzador.
NO970701L (no) Vaksiner inneholdende Borrelia burgdorferi OspG

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701612

Country of ref document: ES